SCHEMBL966033

SCHEMBL966033

COC(=O)CC1=CC=CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.41
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
TSHR P16473 3/20 0.36
ALDH1A1 P00352 4/20 0.35
GAA P10253 3/20 0.35
GFER P55789 1/20 0.35
HSD17B10 Q99714 4/20 0.34
MAPT P10636 3/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 1/20 0.34
MGAM O43451 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TP53 P04637 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610867 0.91 HSP90AB1 (0.36) HSP90AB1CYP4F2CYP4A11TSHRALDH1A1
Carbon Monoxide SCHEMBL964064 0.88 HSP90AB1 (0.34) HSP90AB1CYP4F2CYP4A11
SCHEMBL28304209 0.83 HSP90AB1 (0.38) HSP90AB1CYP4F2CYP4A11TSHRALDH1A1
SCHEMBL1057171 0.81 TSHR (0.43) TSHRALDH1A1HSD17B10MAPTHTT
SCHEMBL11553575 0.79
SCHEMBL29288243 0.79
SCHEMBL13838043 0.78 TSHR (0.47) TSHRALDH1A1HSD17B10MAPTHTT
SCHEMBL4312216 0.77
SCHEMBL9972656 0.76 KMT2A (0.31) LMNAKMT2A
SCHEMBL25285182 0.74 HDAC4 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250152728-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-05-15 US disclosed
US-20230321267-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
US-11759526-B2 Method and molecules MEDIMMUNE, LLC (US) 2023-09-19 US disclosed
EP-4223319-A2 METHOD AND MOLECULES MedImmune, LLC (US) 2023-08-09 EP disclosed
EP-3630732-B1 METHOD AND MOLECULES MEDIMMUNE LLC (US) 2023-07-12 EP disclosed
CN-110650947-B Methods and molecules 免疫医疗有限责任公司 2023-05-12 CN disclosed
US-20200206359-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-07-02 US disclosed
EP-3630732-A1 METHOD AND MOLECULES Medimmune, LLC (US) 2020-04-08 EP disclosed
CN-110650947-A Methods and molecules 免疫医疗有限责任公司 2020-01-03 CN disclosed
WO-2018218093-A1 METHOD AND MOLECULES MEDIMMUNE, LLC (US) 2018-11-29 WO disclosed
US-20160145212-A1 ACETYL-COA CARBOXYLASE MODULATORS MONSANTO TECHNOLOGY LLC (US) 2016-05-26 US disclosed
US-8389572-B2 Therapeutic delivery of carbon monoxide HEMOCORM LIMITED (GB) 2013-03-05 US disclosed
US-8389572-B2 Therapeutic delivery of carbon monoxide HEMOCORM LIMITED (GB) 2013-03-05 US disclosed
US-8389572-B2 Therapeutic delivery of carbon monoxide HEMOCORM LIMITED (GB) 2013-03-05 US disclosed
US-20110015263-A1 THERAPEUTIC DELIVERY OF CARBON MONOXIDE HEMOCORM LIMITED 2011-01-20 US disclosed
US-20110015263-A1 THERAPEUTIC DELIVERY OF CARBON MONOXIDE HEMOCORM LIMITED 2011-01-20 US disclosed
US-20110015263-A1 THERAPEUTIC DELIVERY OF CARBON MONOXIDE HEMOCORM LIMITED 2011-01-20 US disclosed
EP-1978952-A2 THERAPEUTIC DELIVERY OF CARBON MONOXIDE Hemocorm Limited (GB) 2008-10-15 EP disclosed
WO-2007085806-A2 THERAPEUTIC DELIVERY OF CARBON MONOXIDE HEMOCORM LIMITED (GB) 2007-08-02 WO disclosed
WO-2007085806-A2 THERAPEUTIC DELIVERY OF CARBON MONOXIDE HEMOCORM LIMITED (GB) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250152728-A1 Method And Molecules PAICS, EPCAM, SQLE HSP90AB1 2508/4885CYP4F2 259/4885CYP4A11 856/4885
US-20160145212-A1 ACETYL-COA CARBOXYLASE MODULATORS ACACA, ACACB, ACAT2 HSP90AB1 1022/4885CYP4F2 1312/4885CYP4A11 2174/4885
US-20200206359-A1 Method And Molecules PAICS, EPCAM, SQLE HSP90AB1 2508/4885CYP4F2 259/4885CYP4A11 856/4885
US-20230321267-A1 Method And Molecules PAICS, EPCAM, SQLE HSP90AB1 2508/4885CYP4F2 259/4885CYP4A11 856/4885
US-20110015263-A1 THERAPEUTIC DELIVERY OF CARBON MONOXIDE MB, TFRC, CYC1 HSP90AB1 945/4885CYP4F2 695/4885CYP4A11 1893/4885
US-11759526-B2 Method and molecules PAICS, EPCAM, SQLE HSP90AB1 2508/4885CYP4F2 259/4885CYP4A11 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.